-
公开(公告)号：US07943629B2
公开(公告)日：2011-05-17
申请号：US11759479
申请日：2007-06-07
申请人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
发明人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
IPC分类号： C07D239/48 , A61K31/506
CPC分类号： C07D401/12 , C07D239/48
摘要： The invention relates to sulphimides as protein kinase inhibitors of the general formula I
摘要翻译： 本发明涉及作为通式I的蛋白激酶抑制剂的硫酰亚胺
-
2.发明申请NOVEL HETARYL-PHENYLENEDIAMINE-PYRIMIDINES AS PROTEIN KINASE INHIBITORS 审中-公开作为蛋白激酶抑制剂的新型食品 - 苯二胺 - 嘧啶公开(公告)号：US20080176866A1
公开(公告)日：2008-07-24
申请号：US11960118
申请日：2007-12-19
IPC分类号： A61K31/495 , C07D239/28 , A61P35/00
CPC分类号： C07D239/48 , C07D239/47 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D417/12
摘要： The invention relates to novel hetaryl-phenylenediamine-pyrimidines and to their structurally related oxygen and sulphur analogues of the general formula I, processes for their preparation, and their use as medicaments.
摘要翻译： 本发明涉及新型的杂芳基 - 苯二胺 - 嘧啶及其结构相关的通式I的氧和硫类似物，其制备方法及其作为药物的用途。
-
3.发明授权Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 有权磺酰亚胺取代的嘧啶作为CDK和/或VEGF抑制剂，其生产和用作药剂公开(公告)号：US07338958B2
公开(公告)日：2008-03-04
申请号：US10966098
申请日：2004-10-18
IPC分类号： A61K31/506 , C07D239/34 , C07D239/38 , C07D239/48 , A61P35/00 , C07D239/30 , C07D239/56 , C07C315/04 , C07C317/14 , C07C307/02 , C07C311/07
CPC分类号： C07D239/47 , C07D239/48
摘要： This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式I的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4， R 5，X 5和m具有说明书中所含的含义，作为细胞周期蛋白依赖性激酶和VEGF-受体酪氨酸激酶的抑制剂，其生产及其用途 用于治疗各种疾病的药物。
-
公开(公告)号：US20080167330A1
公开(公告)日：2008-07-10
申请号：US11892967
申请日：2007-08-28
IPC分类号： A61K31/505 , C07D239/48 , C07D239/47 , C07D409/04 , A61P35/00 , C07D239/42 , C07D239/34 , C07D403/02 , A61K31/513 , A61K31/506
CPC分类号： C07D239/47 , C07D239/48 , C07D403/12
摘要： The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula 1.
摘要翻译： 本发明涉及作为通式1的蛋白激酶抑制剂的氨基甲酰基亚砜。
-
5.发明授权N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 失效作为CDK和/或VEGF抑制剂的N-芳基 - 亚磺酰亚胺取代的嘧啶，它们的生产和用作药剂公开(公告)号：US07456191B2
公开(公告)日：2008-11-25
申请号：US11386111
申请日：2006-03-22
IPC分类号： A01N43/54 , A61K31/505 , C07D239/02
CPC分类号： C07D239/48 , C07D239/47 , C07D239/50 , C07D333/48 , C07D401/12 , C07D405/12 , C07D409/12
摘要： This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式（I）的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4，R 5，X和m具有本说明书所含的含义，作为细胞周期蛋白依赖性激酶和VEGF- 受体酪氨酸激酶，它们的生产以及它们作为用于治疗各种疾病的药物的用途。
-
公开(公告)号：US20080058358A1
公开(公告)日：2008-03-06
申请号：US11759479
申请日：2007-06-07
申请人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
发明人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
IPC分类号： A61K31/505 , A61K31/506 , A61P35/00 , C07D239/30 , C07D239/48 , C07D401/12
CPC分类号： C07D401/12 , C07D239/48
摘要： The invention relates to sulphimides as protein kinase inhibitors of the general formula I
摘要翻译： 本发明涉及作为通式I的蛋白激酶抑制剂的硫酰亚胺
-
7.发明申请N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 失效N-芳基 - 亚磺酰亚胺取代的嘧啶作为CDK和/或VEGF抑制剂，它们的生产和用作药剂公开(公告)号：US20060229325A1
公开(公告)日：2006-10-12
申请号：US11386111
申请日：2006-03-22
IPC分类号： A61K31/513 , A61K31/506 , C07D417/02
CPC分类号： C07D239/48 , C07D239/47 , C07D239/50 , C07D333/48 , C07D401/12 , C07D405/12 , C07D409/12
摘要： This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式（I）的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4，R 5，X和m具有本说明书所含的含义，作为细胞周期蛋白依赖性激酶和VEGF- 受体酪氨酸激酶，它们的生产以及它们作为用于治疗各种疾病的药物的用途。
-
8.发明申请Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 有权磺酰亚胺取代的嘧啶作为CDK和/或VEGF抑制剂，其生产和用作药剂公开(公告)号：US20050176743A1
公开(公告)日：2005-08-11
申请号：US10966098
申请日：2004-10-18
IPC分类号： A61K31/506 , A61K31/513 , C07D239/46 , C07D239/48 , C07D43/02
CPC分类号： C07D239/47 , C07D239/48
摘要： This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式I的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4， R 5，X 5和m具有说明书中所含的含义，作为细胞周期蛋白依赖性激酶和VEGF-受体酪氨酸激酶的抑制剂，其生产及其用途 用于治疗各种疾病的药物。
-
公开(公告)号：US07312225B2
公开(公告)日：2007-12-25
申请号：US10644076
申请日：2003-08-20
IPC分类号： A61P35/00 , A61K31/505 , C07D245/00
CPC分类号： C07D239/42 , C07D239/48 , C07D409/12 , C07D487/08 , C07D513/08
摘要： Macrocyclic pyrimidine derivatives of general formula I in which R1 to R5, X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.
摘要翻译： R 1至R 5，X，Y，A，B，m和n的通式I的大环嘧啶衍生物具有说明书中所含的含义， 作为细胞周期蛋白依赖性激酶的抑制剂，其生产方法以及它们作为用于治疗各种疾病的药物的用途。
-
![Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors](/abs-image/US/2016/03/15/US09284317B2/abs.jpg.150x150.jpg)
公开(公告)号：US09284317B2
公开(公告)日：2016-03-15
申请号：US13994335
申请日：2011-12-13
申请人： Marcus Koppitz , Ulrich Klar , Rolf Jautelat , Dirk Kosemund , Rolf Bohlmann , Benjamin Bader , Philip Lienau , Gerhard Siemeister
发明人： Marcus Koppitz , Ulrich Klar , Rolf Jautelat , Dirk Kosemund , Rolf Bohlmann , Benjamin Bader , Philip Lienau , Gerhard Siemeister
IPC分类号： A61K31/4985 , C07D241/36 , C07D487/04 , C07D403/02
CPC分类号： C07D487/04 , C07D403/02
摘要： The present invention relates to substituted imidazopyrazine compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
摘要翻译： 本发明涉及通式（I）的取代的咪唑并嗪化合物：其中R 1，R 2，R 3，R 4和R 5如权利要求中所定义，涉及制备所述化合物的方法和中间体，药物组合物和组合，其包含所述 化合物和所述化合物用于制备用于治疗或预防疾病，特别是高增殖和/或血管生成障碍的药物组合物作为唯一试剂或与其它活性成分组合的用途。
-
-
-
-
-
-
-
-
-
搜索结果
93 条记录 (耗时 0.026 秒)
